The CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

home / investigator-perspectives / the-clear-trial-lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma

Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Memorial Sloan Kettering Cancer Center’s Chung-Han Lee, MD, PhD, and Kiran Kehoe, RN, BSN, CCRN.